Physician Education: Bridging Clinical Research and Patient Care

CME Webcast

CME Webcast

Please read this page before participating in this activity. At the bottom of the page, click on “I have read these instructions and understand them,” to begin activity.

HCV Drug Interactions: Trials, Tribulations, and Downright Confusion: A Case-Based Discussion

Author(s): Charles W. Flexner, MD
Airdate: July 27, 2012 (31 minutes, 31 seconds)
CME hours: 0.50 (expires July 27, 2013)
Presented at: Management of Hepatitis C Virus in the New Era: Small Molecules Bring Big Changes
Course Chair(s): Michael S Saag MD, David L Thomas MD, MPH

Grant support:

Request for grants has been made to commercial companies with competing products. Support is from the following:

PLATINUM SUPPORTER
Vertex Pharmaceuticals

GOLD SUPPORTERS
Abbott Laboratories
Gilead Sciences, Inc
Merck & Co, Inc

SILVER SUPPORTER
Janssen Therapeutics

CME Information:

The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The IAS–USA designates this enduring material for a maximum of 6.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians who claimed CME credit for attending the live CME course on which this activity is based may not claim credit for participating in this activity.

Disclosure of Financial Affiliations

In the interest of maintaining the independence of its continuing medical education (CME) activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education (ACCME), the IAS–USA requires all persons with control of content (ie, faculty, IAS–USA Board members, and program staff) to disclose any financial relationships that they or their spouses or partners have had with commercial companies within the past 12 months. Any real or apparent conflicts of interest of those parties are resolved prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in an IAS–USA CME activity.

IAS–USA Board of Directors

Constance A. Benson, MD
Dr Benson has no relevant financial affiliations to disclose. Disclosure information for her spouse, Robert T. Schooley, MD, is indicated below. (Updated 2/4/14)

Peter Cassat, JD
Mr Cassat has no relevant financial affiliations to disclose. (Updated 05/30/12)

Judith S. Currier, MD
Dr Currier has received research grants awarded to the University of California Los Angeles from Merck & Co, Inc. and has served as a consultant to Gilead Sciences, Inc, and ViiV Healthcare. (Updated 2/4/14)

Carlos del Rio, MD
Dr del Rio has no relevant financial affiliations to disclose. (Updated 2/4/14)

Joel E. Gallant, MD, MPH
Dr Gallant has served as a consultant or advisor to Gilead Sciences, Inc, Merck & Co, Inc, Janssen Therapeutics, and Takara Bio Inc; and has received research grants or contracts awarded to his institution from Bristol-Myers Squibb, Gilead Sciences, Inc, Merck & Co, Inc, Sangamo BioSciences, Vertex Pharmaceuticals, Inc, and ViiV Healthcare. (Updated 2/24/14)

Roy M. Gulick, MD, MPH
Dr Gulick serves as a co-investigator on research grants awarded to Weill Cornell Medical College from GlaxoSmithKline/ViiV Healthcare. (Updated 12/02/13)

Donna M. Jacobsen
Ms Jacobsen has no relevant financial affiliations to disclose. (Updated 1/28/14)

Douglas D. Richman, MD
Dr Richman has been a consultant to Bristol-Myers Squibb, Chimerix, Gen-Probe, Inc, Gilead Sciences, Inc, Sirenas, Prism and Monogram Biosciences, Inc. He owns stock from Chimerix. (Updated 2/7/14)

Michael S. Saag, MD
Dr Saag has received grants and research support from Abbvie, Boehringer Ingelheim Pharmaceuticals, Inc, Gilead Sciences, Inc, GlaxoSmithKline, Janssen Therapeutics, Merck & Co, Inc, and ViiV Healthcare. (Updated 03/11/14)

Robert T. Schooley, MD
Dr Schooley has received research support from Bristol-Myers Squibb and Boehringer Ingelheim Pharmaceuticals, Inc, and has served as a scientific advisor to CytoDyn and Merck & Co, Inc, as a scientific advisory board member for Gilead Sciences, Inc, GlobeImmune, Inc, and Monogram Biosciences, and as a member of data monitoring committees for Axio and Gilead Sciences, Inc. He has stock in GlobeImmune, Inc. (Updated 2/4/14)

Paul A. Volberding, MD
Dr Volberding has served on scientific advisory boards for Bristol-Myers Squibb and Gilead Sciences, Inc. (Updated 2/4/14)

Course Faculty and Staff:

Dr Flexner has received grants and research support from GlaxoSmithKline. He has served as a consultant and/or scientific advisory board member for Bristol-Myers Squibb, Merck & Co, Inc, Roche Laboratories, Vertex Pharmaceuticals, Inc, and ViiV Healthcare. (Updated 05/18/12)

Dr Naggie has received research support from Anadys Pharmaceuticals, Inc, Medtronic, Synexis, and Vertex Pharmaceuticals, Inc. She has served as a scientific advisor to Bristol-Myers Squibb and Vertex Pharmaceuticals, Inc. (Updated 05/18/12)

Dr Peters has served as a consultant to Merck & Co, Inc. She has served on data safety monitoring board for Biotron. She has served as a scientific advisor to Clinical Care Options. (Updated 05/18/12)

Dr Saag has received grants and research support from and/or has been a scientific advisor to Ardea Biosciences, Inc, Avexa Ltd, Boehringer Ingelheim Pharmaceuticals, Inc, Bristol-Myers Squibb, Gilead Sciences, Inc, GlaxoSmithKline, Merck & Co, Inc, Pfizer Inc, Tibotec Therapeutics, Vertex Pharmaceuticals, Inc, and ViiV Healthcare. (Updated 05/02/12)

Dr Shaw has no relevant financial affiliations to disclose. (Updated 05/11/12)

Dr Sherman has served as a consultant to Abbott Molecular, Bristol-Myers Squibb, Fibrogen, Merck & Co/Schering-Plough Corp, and Vertex Pharmaceuticals, Inc. He has served on data and safety monitoring boards and endpoint adjudication committees for MedPace, and Tibotec Therapeutics. His institution has received research support from Abbott Laboratories, Anadys, Boeringel-Ingelheim, Bristol-Myers Squibb, Genentech, Gilead Sciences, Inc, Merck & Co/Schering-Plough, Norvartis, SciClone, and Vertex Pharmaceuticals, Inc. (Updated 05/18/12)

Dr Thomas has received grants and research support from Gilead Sciences, Inc, and Merck & Co, Inc. He has served as a consultant to Merck & Co, Inc. (Updated 05/24/12)

Dr Wyles has received grants awarded to the University of California San Diego from Gilead Sciences, Inc, Pharmasset, Inc, and Vertex Pharmaceuticals. He also served as a consultant to Bristol-Myers Squibb and Merck & Co, Inc. He has developed educational presentations for QuantiaMD. (Updated 05/24/12)

IAS–USA CME Staff

Donna M. Jacobsen, Executive Director, has no relevant financial affiliations to disclose (see above).

Cristin M. Toth, CME Project Manager, has no relevant financial affiliations to disclose. (Updated 10/24/13)

CME Evaluation and Claim Forms

After viewing this webcast, please submit your evaluation form to claim credit.

Contact Information

If you have any questions about this web-based CME activity, please contact the IAS–USA:
425 California Street
Suite 1450
San Francisco, CA   94104-2120
Telephone: 415-544-9400
Fax: 415-544-9401
E-mail: registration@iasusa.org